{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T17:30:28Z","timestamp":1770139828895,"version":"3.49.0"},"reference-count":105,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T00:00:00Z","timestamp":1606521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>IgA nephropathy is the most common primary glomerulonephritis with potentially serious outcome leading to end stage renal disease in 30 to 50% of patients within 20 to 30 years. Renal biopsy, which might be associated with risks of complications (bleeding and others), still remains the only reliable diagnostic tool for IgA nephropathy. Therefore, the search for non-invasive diagnostic and prognostic markers for detection of subclinical types of IgA nephropathy, evaluation of disease activity, and assessment of treatment effectiveness, is of utmost importance. In this review, we summarize treatment options for patients with IgA nephropathy including the drugs currently under evaluation in randomized control trials. An early initiation of immunosupressive regimens in patients with IgA nephropathy at risk of progression should result in the slowing down of the progression of renal function to end stage renal disease.<\/jats:p>","DOI":"10.3390\/ijms21239064","type":"journal-article","created":{"date-parts":[[2020,11,29]],"date-time":"2020-11-29T21:00:57Z","timestamp":1606683657000},"page":"9064","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Emerging Modes of Treatment of IgA Nephropathy"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6733-2857","authenticated-orcid":false,"given":"Dita","family":"Maixnerova","sequence":"first","affiliation":[{"name":"1st Faculty of Medicine, General University Hospital, Department of Nephrology, Charles University, 128 08 Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Tesar","sequence":"additional","affiliation":[{"name":"1st Faculty of Medicine, General University Hospital, Department of Nephrology, Charles University, 128 08 Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Moriyama, T., Tanaka, K., Iwasaki, C., Oshima, Y., Ochi, A., Kataoka, H., Itabashi, M., Takei, T., Uchida, K., and Nitta, K. (2014). Prognosis in IgA nephropathy: 30-year analysis of 1012 patients at a single center in Japan. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0091756"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1056\/NEJMra1206793","article-title":"IgA nephropathy","volume":"368","author":"Wyatt","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/ki.2009.243","article-title":"Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, The Oxford classification of IgA nephropathy: Rationale, clinicopathological correlations, and classification","volume":"76","author":"Cattran","year":"2009","journal-title":"Kidney Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/ki.2010.43","article-title":"Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults","volume":"77","author":"Coppo","year":"2010","journal-title":"Kidney Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1681\/ASN.2007050526","article-title":"Remission of proteinuria improves prognosis in IgA nephropathy","volume":"18","author":"Reich","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/ki.2015.322","article-title":"Oxford Derivation, North American Validation and VALIGA Consortia, The MEST score provides earlier risk prediction in lgA nephropathy","volume":"89","author":"Barbour","year":"2016","journal-title":"Kidney Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1681\/ASN.2016040433","article-title":"A multicenter study of the predictive value of crescents in IgA nephropathy","volume":"28","author":"Barbour","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_8","unstructured":"Haas, M., Verhave, J.C., Liu, Z.-H., Alpers, C.E., Barratt, J., Becker, J.U., Cattran, D., Cook, H.T., Coppo, R., and Feehally, J. (2012). Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet, 8."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ng.3118","article-title":"Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens","volume":"46","author":"Kiryluk","year":"2014","journal-title":"Nat. Genet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/ki.1997.361","article-title":"Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG","volume":"52","author":"Tomana","year":"1997","journal-title":"Kidney Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1172\/JCI5535","article-title":"Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies","volume":"104","author":"Tomana","year":"1999","journal-title":"J. Clin. Investig."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1093\/ndt\/gfr448","article-title":"IgA1 immune complexes from pediatric patients with IgA nephropathy activate cultured human mesangial cells","volume":"26","author":"Novak","year":"2011","journal-title":"Nephrol. Dial Transpl."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1681\/ASN.2014101000","article-title":"Current understanding of the role of complement in IgA nephropathy","volume":"26","author":"Maillard","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4049\/jimmunol.1302249","article-title":"The combined role of galactose-deficient IgA1 and streptococcal IgA-binding M protein in inducing IL-6 and C3 secretion from human mesangial cells: Implications for IgA nephropathy","volume":"193","author":"Schmitt","year":"2014","journal-title":"J. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"F945","DOI":"10.1152\/ajprenal.00423.2007","article-title":"Activation of podocytes by mesangial-derived TNF-alpha: Glomerulo-podocytic communication in IgA nephropathy","volume":"294","author":"Lai","year":"2008","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_16","unstructured":"KDIGO (2012). KDIGO clinical practice guideline for glomerulonephritis. Kidney Int., 2, 139\u2013274."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00467-017-3652-1","article-title":"The gut-kidney axis in IgA nephropathy: Role of microbiota and diet on genetic predisposition","volume":"33","author":"Coppo","year":"2018","journal-title":"Pediatr. Nephrol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.nephro.2018.02.004","article-title":"Recent advances in the physiopathology of IgA nephropathy","volume":"14","author":"Monteiro","year":"2018","journal-title":"Nephrol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/ki.2015.94","article-title":"Gluten exacerbates IgA nephropathy in humanized mice through gliadin-CD89 interaction","volume":"88","author":"Papista","year":"2015","journal-title":"Kidney Int."},{"key":"ref_20","first-page":"3","article-title":"Is the dietary protein restriction achievable in chronic kidney disease? The impact upon quality of life and the dialysis delay","volume":"15","author":"Koulouridis","year":"2011","journal-title":"Hippokratia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1161\/01.HYP.38.1.81","article-title":"Sodium sensitivity of blood pressure appearing before hypertension and related to histological damage in immunoglobulin a nephropathy","volume":"38","author":"Konishi","year":"2001","journal-title":"Hypertension"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"274","DOI":"10.5414\/CNP72274","article-title":"Sodium-sensitive variability of the antiproteinuric efficacy of RAS inhibitors in outpatients with IgA nephropathy","volume":"72","author":"Suzuki","year":"2009","journal-title":"Clin. Nephrol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Ouyang, Y., Xie, J., Yang, M., Zhang, X., Ren, H., Wang, W., and Chen, N. (2016). Underweight is an independent risk factor for renal function deterioration in patients with IgA nephropathy. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0162044"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/jcla.21778","article-title":"Impact of Body Mass Index on progression of IgA nephropathy among Japanese patients","volume":"29","author":"Shimamoto","year":"2015","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1053\/j.jrn.2014.01.016","article-title":"The beneficial effects of weight reduction in overweight patients with chronic proteinuric immunoglobulin a nephropathy: A randomized controlled trial","volume":"24","author":"Kittiskulnam","year":"2014","journal-title":"J. Ren. Nutr."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3349\/ymj.2016.57.1.209","article-title":"Smoking-related renal histologic injury in IgA nephropathy patients","volume":"57","author":"Cha","year":"2016","journal-title":"Yonsei Med. J"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1681\/ASN.2015010030","article-title":"IgA Nephritis with Declining Renal Function: Treatment with Corticosteroids May Be Worthwhile","volume":"26","author":"Ponticelli","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_28","first-page":"CD007751","article-title":"Angiotension-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3)non-diabetic chronic kidney disease","volume":"10","author":"Sharma","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1681\/ASN.2018101017","article-title":"Mortality in IgA nephropathy: A nationwide population-based cohort study","volume":"30","author":"Jarrick","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.ASN.0000103869.08096.4F","article-title":"Corticosteroid effectiveness in IgA nephropathy: Long-term results of a randomized, controlled trial","volume":"15","author":"Pozzi","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1681\/ASN.2011111112","article-title":"TESTING Study Group. Corticosteroid therapy in IgA nephropathy","volume":"23","author":"Lv","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1681\/ASN.2014070697","article-title":"VALIGA study of the ERA-EDTA Immunonephrology Working Group. Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study","volume":"26","author":"Tesar","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2017.9362","article-title":"TESTING Study Group. Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial","volume":"318","author":"Lv","year":"2017","journal-title":"JAMA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.kint.2018.10.018","article-title":"Management and treatment of glomerular diseases (part 1): Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"95","author":"Floege","year":"2019","journal-title":"Kidney Int."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"STOP-IgAN Investigators. Intensive Supportive Care plus Immunosuppression in IgA Nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.kint.2020.04.046","article-title":"After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy","volume":"98","author":"Rauen","year":"2020","journal-title":"Kidney Int."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","article-title":"NEFIGAN Trial Investigators. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): A double-blind, randomised, placebo-controlled phase 2b trial","volume":"389","author":"Barratt","year":"2017","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1681\/ASN.2015080856","article-title":"IgA1 Protease Treatment Reverses Mesangial Deposits and Hematuria in a Model of IgA Nephropathy","volume":"27","author":"Lechner","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1084\/jem.20112005","article-title":"Transglutaminase is essential for IgA nephropathy development acting through IgA receptors","volume":"209","author":"Berthelot","year":"2012","journal-title":"J. Exp. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/ki.2009.168","article-title":"The Oxford classification of IgA nephropathy: Pathology definitions, correlations, and reproducibility","volume":"76","author":"Roberts","year":"2009","journal-title":"Kidney Int."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","article-title":"Oxford classification of IgA nephropathy 2016: An update from the IgA Nephropathy Classification Working Group","volume":"91","author":"Trimarchi","year":"2017","journal-title":"Kidney Int."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1093\/ndt\/gfy338","article-title":"Towards a personalized treatment for IgA nephropathy considering pathology and pathogenesis","volume":"34","author":"Coppo","year":"2019","journal-title":"Nephrol. Dial Transpl."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1001\/jamainternmed.2019.0600","article-title":"Evaluating a new international risk-prediction tool in IgA nephropathy","volume":"179","author":"Barbour","year":"2019","journal-title":"JAMA Int. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.kint.2020.04.042","article-title":"Improving treatment decisions using personalized risk assessment from the international IgA nephropathy prediction tool","volume":"98","author":"Barbour","year":"2020","journal-title":"Kidney Int."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2215\/CJN.02300215","article-title":"Changes in Proteinuria and Side Effects of Corticosteroids Alone or in Combination with Azathioprine at Different Stages of IgA Nephropathy","volume":"11","author":"Sarcina","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1681\/ASN.2010010117","article-title":"Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy","volume":"21","author":"Pozzi","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2169\/internalmedicine.53.1136","article-title":"Comparison of glucocorticoids alone and combined with cyclosporine a in patients with IgA nephropathy: A prospective randomized controlled trial","volume":"53","author":"Liu","year":"2014","journal-title":"Intern Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.kjms.2014.04.002","article-title":"Cyclosporine A combined with medium\/low dose prednisone in progressive IgA nephropathy","volume":"30","author":"Xu","year":"2014","journal-title":"Kaohsiung J. Med. Sci"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1053\/j.ajkd.2016.11.027","article-title":"Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: A randomized controlled trial","volume":"69","author":"Hou","year":"2017","journal-title":"Am. J. Kidney Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/ki.2009.499","article-title":"Long-term study of mycophenolate mofetil treatment in IgA nephropathy","volume":"77","author":"Tang","year":"2010","journal-title":"Kidney Int."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1053\/j.ajkd.2015.06.013","article-title":"Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy","volume":"66","author":"Hogg","year":"2015","journal-title":"Am. J. Kidney Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/ndt\/gfw326","article-title":"Mycophenolate mofetil therapy in immunoglobulin a nephropathy: Histological changes after treatment","volume":"32","author":"Beckwith","year":"2017","journal-title":"Nephrol. Dial Transpl."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000456039","article-title":"Rapamycin Enhances Repressed Autophagy and Attenuates Aggressive Progression in a Rat Model of IgA Nephropathy","volume":"45","author":"Liu","year":"2017","journal-title":"Am. J. Nephrol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.ajkd.2019.01.026","article-title":"Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial","volume":"74","author":"Liu","year":"2019","journal-title":"Am. J. Kidney Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"373S","DOI":"10.1093\/ajcn\/71.1.373S","article-title":"Use of fish oil to treat patients with immunoglobulin a nephropathy","volume":"71","author":"Donadio","year":"2000","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000339287","article-title":"Treatment of resistant glomerular diseases with adrenocorticotropic hormon gel: A prospective trial","volume":"36","author":"Bomback","year":"2012","journal-title":"Am. J. Nephrol."},{"key":"ref_58","first-page":"58","article-title":"An open-label pilot study of adrenocorticotrophic hormone in the treatment of IgA nephropathy at high risk of progression","volume":"5","author":"Zand","year":"2020","journal-title":"KI Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/j.ajkd.2014.06.036","article-title":"Tonsillectomy for IgA nephropathy: A meta-analysis","volume":"65","author":"Zand","year":"2015","journal-title":"Am. J. Kidney Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/ndt\/gfu020","article-title":"A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin a nephropathy","volume":"29","author":"Kawamura","year":"2014","journal-title":"Nephrol. Dial Transpl."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000441852","article-title":"VALIGA study of ERA-EDTA Immunonephrology Working Group. Tonsillectomy in a European Cohort of 1,147 Patients with IgA Nephropathy","volume":"132","author":"Feehally","year":"2016","journal-title":"Nephron"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1681\/ASN.2016060640","article-title":"A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction","volume":"28","author":"Lafayette","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000319656","article-title":"Effect of single-dose rituximab on primary glomerular diseases","volume":"117","author":"Sugiura","year":"2011","journal-title":"Nephron Clin. Pract"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/ndt\/gfy064","article-title":"Defective gene expression of the membrane complement inhibitor CD46 in patients with progressive immunoglobulin A nephropathy","volume":"34","author":"Coppo","year":"2018","journal-title":"Nephrol. Dial Transpl."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2215\/CJN.09710913","article-title":"Association of C4d deposition with clinical outcomes in IgA nephropathy","volume":"9","author":"Espinosa","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1681\/ASN.2014010096","article-title":"Variants in complement factor H and complement factor H-related protein genes, CFHR 3 and CFHR1, affect complement activation in IgA nephropathy","volume":"26","author":"Zhu","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1681\/ASN.2015111210","article-title":"Fine mapping implicates a deletion of CFHR1 nad CFHR3 in protection from IgA nephropathy in Han Chinese","volume":"27","author":"Xie","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1681\/ASN.2017010019","article-title":"Deletion variants of CFHR1 and CFHR3 associate with mesangial immune deposits but not with progression of IgA nephropathy","volume":"29","author":"Jullien","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40620-015-0245-6","article-title":"Role of complement in IgA nephropathy","volume":"29","author":"Daha","year":"2016","journal-title":"J. Nephrol."},{"key":"ref_70","first-page":"749","article-title":"Maintenance of remission following completion of OMS721 treatment in patients with IgA nephropathy (IGAN). Abstract SA-PO278","volume":"28","author":"Block","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s10875-013-9970-6","article-title":"C3a, C5a renal expression and their receptors are correlated to severity of IgA nephropathy","volume":"34","author":"Liu","year":"2014","journal-title":"J. Clin. Immunol."},{"key":"ref_72","unstructured":"ChemoCentryx (2016, December 20). Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With Immunoglobulin A Nephropathy on Stable RAAS Blockade, ClinicalTrials.gov [Internet], Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02384317."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor Avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10157-019-01700-1","article-title":"New strategies and perspectives on managing IgA nephropathy","volume":"23","author":"Selvaskandan","year":"2019","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41232-016-0015-4","article-title":"BAFF- and APRIL targeted therapy in systemic autoimmune diseases","volume":"36","author":"Nakayamada","year":"2016","journal-title":"Inflamm Regen."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000481636","article-title":"Immunoglobulin A nephropathy: Advances in understanding of pathogenesis and treatment","volume":"47","author":"Lafayette","year":"2018","journal-title":"Am. J. Nephrol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00467-016-3390-9","article-title":"Biomarkers and targeted new therapies for IgA nephropathy","volume":"32","author":"Coppo","year":"2017","journal-title":"Pediatr. Nephrol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"i25","DOI":"10.1093\/ndt\/gft271","article-title":"Proteasome inhibitors in progressive renal diseases","volume":"29","author":"Coppo","year":"2014","journal-title":"Nephrol. Dial Transpl."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"683","DOI":"10.5301\/jn.5000218","article-title":"Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features","volume":"26","author":"Xin","year":"2013","journal-title":"J. Nephrol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.4049\/jimmunol.1102603","article-title":"Spleen tyrosine kinase is important in the production of proinflammatory cytokines and cell proliferation in human mesangial cells following stimulation with IgA1 isolated from IgA nephropathy patients","volume":"189","author":"Kim","year":"2012","journal-title":"J. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.semnephrol.2018.05.019","article-title":"Role of the Spleen Tyrosine Kinase Pathway in Driving Inflammation in IgA Nephropathy","volume":"38","author":"McAdoo","year":"2018","journal-title":"Semin. Nephrol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"509","DOI":"10.5414\/CPP48509","article-title":"Comparison of the therapeutic effects of leflunomide and mycophenolate mofetil in the treatment of immunoglobulin a nephropathy manifesting with nephrotic syndrome","volume":"48","author":"Liu","year":"2010","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/nep.12359","article-title":"Valsartan combined with clopidogrel and\/or leflunomide for the treatment of progressive immunoglobulin A nephropathy","volume":"20","author":"Cheng","year":"2015","journal-title":"Nephrology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/08830185.2016.1276903","article-title":"Targeting BAFF and APRIL in systemic lupus erythematosus and oTher. antibody-associated diseases","volume":"36","author":"Samy","year":"2017","journal-title":"Int. Rev. Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e3099","DOI":"10.1097\/MD.0000000000003099","article-title":"Increased APRIL expression induces IgA1 aberrant glycosylation in IgA nephropathy","volume":"95","author":"Zhai","year":"2016","journal-title":"Medicine"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1136\/annrheumdis-2013-205067","article-title":"Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE):52-week data (APRIL-SLE randomised trial)","volume":"74","author":"Isenberg","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2147\/DDDT.S114552","article-title":"Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus:evidenc to date","volume":"11","author":"Lenert","year":"2017","journal-title":"Drug Des. Devel Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"26","author":"Richardson","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/ki.2008.579","article-title":"Upregulation of the immunoproteasome in peripheral blood mononuclear cells of patients with IgA nephropathy","volume":"75","author":"Coppo","year":"2009","journal-title":"Kidney Int."},{"key":"ref_90","first-page":"66","article-title":"Phase I trial of bortezomib daily dose: Safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors","volume":"5","author":"Bahleda","year":"2017","journal-title":"Investig. New Drugs"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"i138","DOI":"10.1093\/ndt\/gfw336","article-title":"Targeting the tyrosine kinase signalling pathways for treatment of immune-mediated glomerulonephritis: From bench to bedside and beyond","volume":"32","author":"Ma","year":"2017","journal-title":"Nephrol. Dial Transpl."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/ki.2015.29","article-title":"Correlation of disease activity in proliferative glomerulonephritis with glomerular spleen tyrosine kinase expression","volume":"88","author":"McAdoo","year":"2015","journal-title":"Kidney Int."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1136\/annrheumdis-2014-205361","article-title":"OSKIRA-4: A phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy","volume":"74","author":"Taylor","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1172\/JCI113935","article-title":"Endothelin stimulates phospholipase C, Na+\/H+ exchange, c-Fos expression, and mitogenesis in rat mesangial cells","volume":"83","author":"Simonson","year":"1989","journal-title":"J. Clin. Investig."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/ki.1991.38","article-title":"Urinary excretion of endothelin-1 in normal subjects and patients with renal disease","volume":"39","author":"Ohta","year":"1991","journal-title":"Kidney Int."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1681\/ASN.V12112321","article-title":"Renal endothelin-1 and endothelin receptor type B expression in glomerular diseases with proteinuria","volume":"12","author":"Lehrke","year":"2001","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_97","first-page":"27","article-title":"The influence of three endothelin-1 polymorphisms on the progression of IgA nephropathy","volume":"53","author":"Maixnerova","year":"2007","journal-title":"Folia Biol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"93","DOI":"10.33549\/physiolres.933670","article-title":"Molecular Profiling in IgA Nephropathy and Focal and Segmental Glomerulosclerosis","volume":"67","author":"Tycova","year":"2018","journal-title":"Physiol. Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1159\/000188912","article-title":"Effect of a specific endothelin receptor a antagonist on glomerulonephritis of ddY mice with IgA nephropathy","volume":"72","author":"Nakamura","year":"1996","journal-title":"Nephron"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1681\/ASN.2018010091","article-title":"DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS","volume":"29","author":"Trachtman","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ekir.2019.12.017","article-title":"Study design of the phase 3 sparsentan versus irbesartan (DUPLEX) study in patients with focal segmental glomerulosclerosis","volume":"5","author":"Komers","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/ki.2013.248","article-title":"Role of Nrf2 in protection against acute Kidney injury","volume":"84","author":"Shelton","year":"2013","journal-title":"Kidney Int."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1105351","article-title":"Bardoxolone methyl and kidney function in CKD with type 2 diabetes","volume":"365","author":"Pergola","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_104","unstructured":"Block, G.A. (2018). Primary Efficacy Analyses from a Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients with IgA Nephropathy. ASN Kidney Week, poster TH-PO1039."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.kint.2019.04.027","article-title":"Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease","volume":"96","author":"Rossing","year":"2019","journal-title":"Kidney Int."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/23\/9064\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:39:01Z","timestamp":1760179141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/23\/9064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,28]]},"references-count":105,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["ijms21239064"],"URL":"https:\/\/doi.org\/10.3390\/ijms21239064","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,28]]}}}